FDA clears UltraSight's AI platform for use with a broader range of existing ultrasound devices, aiding novice users in performing echocardiographic exams.
Key Details
- 1UltraSight's AI Echo Stewardship Platform now cleared by FDA for broader ultrasound compatibility.
- 2No new ultrasound equipment is required—compatible with handheld, laptop, and cart-based devices.
- 3Platform provides real-time, AI-assisted guidance for focused cardiac ultrasound (FoCUS) image acquisition.
- 4Aims to reduce variability and improve the usability of cardiac ultrasound by non-sonographer clinicians.
- 5Supports healthcare systems in scaling FoCUS exams without purchasing new hardware.
Why It Matters
By enabling AI-guided echocardiography on existing devices, this clearance lowers adoption barriers, expands cardiac imaging capabilities system-wide, and supports quality imaging by non-experts—potentially easing staff shortages and improving patient care accessibility.
Source
Cardiovascular Business
Related News
•Radiology Business
GE HealthCare’s True Definition DL Receives FDA Clearance for CT Imaging
GE HealthCare's True Definition DL, a deep learning-based CT image reconstruction tool, has received FDA 510(k) clearance.
•Radiology Business
AI Guidance Cuts Novice Ultrasound Exam Time by 34%
AI guidance significantly reduces exam times and enhances diagnostic quality for novice ultrasound operators performing shoulder exams.
•Radiology Business
Lucida Medical Raises $11M for AI-Based Prostate MRI Diagnosis Expansion
Lucida Medical, specializing in AI-assisted prostate cancer diagnosis via MRI, raises $11.4M to drive US FDA approval and platform expansion.